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Increasing global mortality from Idiopathic Pulmonary 
Fibrosis in the 21st century 
John Hutchinson, Tricia McKeever, Andrew Fogarty, Vidya Navaratnam, Richard Hubbard  
Abstract 
Rationale: Recent evidence from the United Kingdom suggests that the number of deaths 
from idiopathic pulmonary fibrosis is increasing, although comparable international data are 
limited.  
Objectives: We aimed to collate death certification data from multiple countries to 
determine global trends in mortality from idiopathic pulmonary fibrosis.  
Methods: Data were obtained from the national statistics agencies of countries with 
relevant mortality records. Age-standardised mortality rates were calculated, and Poisson 
regression modelling was used to calculate rate ratios. Meta-analysis was used to calculate 
an overall estimate of mortality change over time.  
Measurements and Main Results: Ten countries provided mortality data on pulmonary 
fibrosis over a period from 1999 to 2012. Age-standardised mortality ranged between 4 and 
10 per 100,000 population for the most recent years of data, being lowest in Sweden (4.68 
per 100,000), Spain (5.38 per 100,000) and New Zealand (5.55 per 100,000), and highest in 
the UK (9.84 per 100,000 in England and Wales, 10.71 per 100,000 in Scotland) and Japan 
(10.26 per 100,000). Positive associations with male sex and increasing age were 
consistently observed across all countries. There was an overall 2-3% annual increase in 
mortality depending on codes used for classification – for broad codes, overall rate ratio 
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1.03 (95% confidence intervals 1.02-1.04, p<0.001), for narrow codes, overall rate ratio 1.02 
(95% confidence intervals 1.01-1.03, p<0.001). Validation in a local cohort showed that 
idiopathic pulmonary fibrosis was recorded as the underlying cause of death in two-thirds of 
known cases and anywhere on the death certificate in 80% of cases. 
Conclusions: Mortality from idiopathic pulmonary fibrosis is increasing steadily worldwide, 
despite that fact that death certification will almost certainly underestimate true mortality. 
We estimate that there will be between 28000-65000 deaths in Europe and 13000-17000 
deaths in the USA from idiopathic pulmonary fibrosis clinical syndrome in 2014. Variation 
between countries remains but is less than previously reported.   
Abstract word count: 307       
Keywords: idiopathic pulmonary fibrosis, epidemiology, mortality rates 
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Introduction 
There is recent evidence of increasing incidence and mortality from idiopathic 
pulmonary fibrosis (IPF) in the United Kingdom (1), but less evidence from elsewhere in the 
World, with varying estimates from a limited number of historical studies with different 
methodologies (2). Mortality registration statistics, compiled from death certification, are 
the most frequent means of assessing mortality, despite some limitations (1, 3-5), 
particularly ascertainment completeness.  
Mortality statistics are based on the International Classification of Diseases, Tenth 
revision (ICD-10) (6). IPF is classified under the overall code of J84 (‘other interstitial 
pulmonary diseases’), with a specific code of J84.1 (‘other interstitial pulmonary diseases 
with fibrosis’). We have previously selected cases of IPF using both J84.1 and the less 
specific code J84.9 (‘interstitial pulmonary disease, unspecified’), with the rationale that 
many of these cases coded as J84.9 would have IPF (7). The two other codes under overall 
code J84 (J84.0 and J84.8) refer to ‘alveolar and parietoalveolar conditions’ and ‘other 
specified interstitial lung disease’ respectively, and are rarely used. Other idiopathic 
interstitial pneumonias such as non-specific interstitial pneumonia (NSIP) and cryptogenic 
organising pneumonia (COP) may also be classified under J84.1 according to some online 
databases (8, 9) but this is not clear in official guidance (6). Conditions such as sarcoidosis 
(D86), occupational or inhalational interstitial lung disease (J60-70) and connective tissue 
disease associated interstitial lung disease (J99.0, J99.1) are classified elsewhere (6). 
Mortality statistics are collated primarily based on one underlying cause of death (10), but 
additional multiple causes of death, when reported, have been useful in conditions such as 
IPF when the underlying cause of death may be unrelated (11).  
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This study aims to examine mortality from IPF across a number of countries using 
death certification data, in an attempt to assess current mortality rates, changes over time, 
and any regional differences. 
 
Methods 
Cause of death data were obtained from national statistics agencies worldwide. 
Websites were searched for all countries in Europe, North America, Australia, New Zealand, 
and countries in the G20 group of major economies. Underlying cause of death data were 
obtained for J84, and where available, more specific sub-codes (J84.1 and J84.9) were also 
obtained. J84.0 and J84.8 were only rarely used and therefore J84 was assumed to roughly 
approximate J84.1 and J84.9 for countries where sub-classification was unavailable. The 
term IPF-clinical syndrome (IPF-CS) was used to describe identified cases (1, 7), 
acknowledging that a minority may not be ‘true’ IPF. Multiple cause of death data (featuring 
all diseases mentioned on death certification) were obtained in addition to underlying cause 
of death where available: these records would be expected to include all cases where IPF 
was listed as either the underlying cause of death or as a secondary cause.  
For each country, deaths were grouped in the following age categories: 0-44 years, 
45-54 years, 55-64 years, 65-74 years, 75-84 years, 85 years and over. Crude mortality rates 
were calculated per 100,000 population, for ICD-10 codes J84, J84.1 alone, and J84.1 
combined with J84.9. Age-standardised mortality rates were calculated by standardising to 
the 2013 European Standard Population (12). Poisson regression modelling was used to 
calculate mortality rate ratios by sex, age and year, and to calculate trend data for individual 
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countries. Meta-analysis using the random effects model was used to determine an overall 
estimate of change in mortality over time across countries. Data analysis was completed 
using Stata, version 11 (StataCorp, TX, USA).  
To assess the validity of death certification in the UK as a measure of IPF mortality, 
the cause of death data for a recent cohort of patients with confirmed IPF were sought for 
all deaths. This cohort comprised 211 incident cases of IPF from England and Wales, 
recruited from 2010 to 2012 for another study (13), whose imaging had been reviewed by 
two experienced thoracic radiologists and confirmed as definite or probable usual 
interstitial pneumonia (UIP), the histological correlate of IPF, according to 2011 ATS/ERS 
criteria (14).   
 
Results 
Deaths from ICD-10 code J84 were available for England & Wales (2001-2012), 
Australia (2000-2011), Canada (2000-2011), Japan (2009-2011), Northern Ireland (2009-
2011), New Zealand (2006-2010), Scotland (2001-2012), Spain (2000-2011), Sweden (2000-
2012) and the United States (1999-2010). Data for specific codes J84.1 and J84.9 were 
available for England & Wales, Australia, Canada, Spain and USA. Multiple cause of death 
data were available in addition for England & Wales, Australia and the USA. Individual state-
level data were available for the USA, but where values were less than ten deaths, data 
were suppressed for reasons of confidentiality, restricting the ability to calculate age-
specific rates in smaller states. Data were therefore analysed for the largest five states, 
where suppressed data were minimal. Three years of data were outliers: Spain in 2005 (very 
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few deaths recorded) and USA multiple cause of death data in 2006 and 2007 for J84 
(apparent excess of deaths from J84.8 in all states) (Table 1).   
 
Comparison between ICD-10 codes 
For the five countries with all codes available, J84.1 comprised 78-95% of all J84 
codes for underlying cause of death over the years available, with J84.9 comprising 4-20% of 
codes. There was a lower proportion coded as J84.1 in the 0-44 age category. J84.1 and 
J84.9 combined therefore comprised the vast majority of total J84 cases: greater than 98% 
for almost all years of data. While most data from Japan was only available by three-digit 
ICD-10 code (J84), there were overall totals available, by sex, for each of the sub-codes. 
While over 99% were J84.1 and J84.9 combined, 70-75% of cases were sub-classified as 
J84.9, in contrast to elsewhere where the majority were classified as J84.1.  
For reasons of clarity, J84.1 and J84 overall data are presented in the main text, with 
J84.1+J84.9 combined data reported in the data supplement.  
 
Mortality across countries by underlying cause of death 
Using the broad J84 classification, crude mortality varied from 2.54 per 100,000 
population (Sweden, 2000) to 11.08 per 100,000 (Japan, 2011) (Table 2). Age-standardised 
mortality rates were highest in Northern Ireland, Scotland and Japan, and lowest in Sweden, 
Spain and New Zealand (Figure 1, Table 2), varying from 4.68 to 13.36 per 100,000 for the 
latest years available. 
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Males had consistently higher mortality than females, with mortality rate ratios for 
male sex from 1.59 in the USA (95% confidence interval (CI) 1.57-1.60, p<0.001) to 2.68 in 
Japan (95% CI 2.63-2.74). Meta-analysis of rate ratios for male vs female sex showed an 
overall estimate of 2.06 (95% CI 1.77-2.40, p<0.001, see Figure E1, data supplement). 
Mortality was significantly higher with increasing age. Mortality rates broadly increased over 
time for all countries. Adjusted annual increases in mortality ranged from 1-4%, with the 
exception of Northern Ireland where there was limited data and a large rise. The rate of 
increase was highest for England & Wales, Scotland and Japan (4%), and lowest for the USA 
(1%). Meta-analysis of mortality rate ratios over time showed an annual 3% increase over 
time (1.03, 95% CI 1.02-1.04, p<0.001) (Figure 1).  
Using the more precise J84.1 coding, crude and age-standardised mortality rates 
were slightly lower but in similar proportions across the countries (Table 3 / Figure 2). The 
highest age-standardised rate was in England & Wales (8.28 per 100,000, in 2012), and the 
lowest in Spain (4.64 per 100,000, in 2011). Rate ratios for increasing age vs younger age 
were higher than using the broader J84 code.  Rate ratios again increased over time for all 
countries, with the highest annual increase in England & Wales (annual increase 1.03, 95% 
CI 1.027-1.034, p for trend <0.001) and the lowest in the USA (annual increase 1.01, 95% CI 
1.011-1.014, p for trend <0.001). Meta-analysis of rate ratios over time showed a 2% 
increase over time (rate ratio 1.02, 95% CI 1.01-1.03, p<0.001) (Figure 2).  
We repeated the analysis excluding deaths under age 65 years, to enhance 
specificity of cases for IPF. Summary rate ratios by meta-analysis remained the same for all 
ICD-10 codes. We also performed a sensitivity analysis for J84 data excluding Japan and 
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Northern Ireland (countries with only three years of data), but there was no change in the 
meta-analysis.   
Mortality using multiple cause of death data 
Multiple cause of death data from the USA, Australia and England & Wales yielded 
considerably more deaths in each country (see Table 1).  Age-standardised mortality rates 
were consequently higher than when examining underlying cause of death, and highest in 
England & Wales – for J84.1, mortality was 12.98 per 100,000 in 2010, compared to 9.85 per 
100,000 in Australia, and 9.37 per 100,000 in the USA (Figure 3). Data for the broad code J84 
were not analysed due to concerns over accuracy in the USA data (erroneous raw data for 
2006/2007). 
For England & Wales, mortality rate ratios over time were similar to underlying cause 
of death data.  However, the rate of increase was less for Australia, and there was no 
increase over time in the USA. Using Poisson regression for combined USA, Australia and 
England & Wales data (years with data available for all three countries) there was less 
chance of having a diagnostic code of J84.1 in the USA compared to England & Wales (rate 
ratio 0.87, 95% CI 0.86-0.88, p <0.001), and also less chance in Australia (rate ratio 0.83, 95% 
CI 0.81-0.85, p<0.001) (Table 4). The mutually adjusted (for age and sex) mortality rate ratio 
for annual change was 1.00 (95% CI 1.001-1.003, p for trend=0.004). Meta-analysis using the 
random effects method (including all years with data available) showed individual rates of 
1.03 for England & Wales (95% 1.027-1.032, p<0.001), 1.01 for Australia (95% CI 1.00-1.01, 
p=0.016), and 1.00 for USA (95% CI 0.999-1.001, p=0.701) (Table 4), with an overall rate of 
1.01 (0.99-1.03, p=0.280).  
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Subnational data from the USA was limited due to suppressed data where there 
were small numbers of deaths. Using multiple cause of death data, crude mortality rates 
were available for all states, and ranged from 3.18 per 100,000 (Nevada) to 9.75 per 
100,000 (Vermont) in 2010 for code J84.1. For the top 5 most populous states (California, 
Texas, New York, Florida, Illinois) with full age-specific data, the highest rates were in Texas 
(crude rate 5.44 per 100,000, age-standardised rate 10.69 per 100,000) and lowest in New 
York (crude rate 4.29 per 100,000, age standardised rate 6.42 per 100,000) (Table 5). While 
crude mortality rates increased over time, age-standardised rates remained relatively 
stable. Rate ratios for annual increase over time showed a marginal increase for Florida, 
Illinois and New York, but a marginal decrease for California and Texas, with an overall rate 
ratio by meta-analysis of 1.00 (95% CI 0.99-1.01, p=0.687). 
Repeating the analysis for each country using multiple cause of death data excluding 
those aged under 65 made no change to summary rate ratio estimates for either code. 
Validity of death certification 
In the UK cohort study to date, there were 124 deaths out of 211 patients with IPF 
(median follow-up 2 years). Of these, 83 (67%) had IPF-CS coded as an underlying cause of 
death, and 102 (82%) had it elsewhere on the death certificate. For 8 of these patients, the 
code used was J84.9, whereas the remaining 116 used J84.1. There was considerably 
variability in text used on certificates, including idiopathic pulmonary fibrosis, pulmonary 
fibrosis, idiopathic fibrosing alveolitis, usual interstitial pneumonia, and interstitial lung 
disease. The latter two were coded as J84.9, even though both would be reasonable clinical 
calls as IPF. One case was classed as non-specific interstitial pneumonia (NSIP) and coded as 
J84.9. Of the 41 patients with alternative underlying causes of deaths, the majority were 
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due to ischaemic heart disease or cardiac failure (16 patients) and lung cancer (8 patients). 
Three patients had COPD chosen as the underlying cause of death when in text form it 
appeared to be given equal status to IPF. 
 
Discussion 
This study has shown worldwide variation in mortality from IPF-CS. Crude mortality 
rates varied from 3 per 100,000 to 9 per 100,000, being lowest in New Zealand, Sweden and 
Spain, and highest in the UK and Japan. There was an increase in age-standardised mortality 
rates over time in most countries studied that was more pronounced in some, such as the 
UK. The rate of increase was least in the USA, where rates were lower than in the UK, and 
using multiple cause mortality data there was no apparent increase over the time period 
studied. The clear association with male sex and increasing age described previously was 
confirmed across all countries in this study. Multiple cause of death data revealed 
considerably more deaths where IPF-CS was listed anywhere on the death certificate, 
strongly suggesting that it is often not listed as the underlying cause of death. Analysis of 
cause of death in a UK cohort of IPF patients revealed that IPF-CS was listed as the 
underlying cause of death in 2/3 of cases, and anywhere on the death certificate in 80%, 
suggesting mortality data may underestimate incidence by 20-30%.  
The strengths of our study are the inclusion of international data from many 
countries, including some not previously studied, and that we have focussed on data from 
the first decade of the 21st century, which has only previously been assessed in England & 
Wales (1). This has allowed consistent use of more contemporary ICD-10 codes. We have 
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also been able to compare alternative coding methods, and both underlying and multiple 
cause mortality data for three countries. Our validation cohort is also the most recent 
attempt to assess the reported cause of death of patients with IPF, following previous work 
in the 1990s from the UK (15) and USA (5), and continues to show that death certification 
underestimates disease burden. The use of meta-analysis to combine national disease 
incidences gives a global composite estimate that can be considered a synthesis of the best 
available data into global summary statistics, with the high heterogeneity statistics an 
inevitable consequence of comparisons between different populations and cultures. 
The key limitations of our study relate to the variability in cause of death data and its 
reliability. Although our validation cohort analysis shows that more patients with IPF have 
the disease listed on their death certificate than in earlier studies (5, 15), a significant 
proportion of patients with IPF will die from another cause, particularly cardiovascular 
disease or lung cancer, and even if IPF is listed as a contributing factor, multiple cause of 
death data are not as widely published. When IPF is the underlying cause of death, it may be 
misclassified or misdiagnosed, depending on the extent of diagnostic work-up prior to 
death, and also due to coding irregularities, and our validation cohort analysis provides 
evidence that cases of confirmed IPF are sometimes coded as ‘unspecified’ (ICD-10 code 
J84.9). ICD-10 code J84.1 is the most specific code for IPF, and this is supported by it being 
less common in younger patients, with higher rate ratios for increasing age, consistent with 
IPF being a disease of older people (16, 17). However, using J84.1 may miss these 
unspecified cases and so may underestimate mortality. Using broader codes is less accurate 
but likely closer approximates to true numbers. It is therefore likely that the combination of 
data used in our study for IPF-CS gives a reasonable estimation of true IPF mortality. Our 
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validation cohort was only from one country (England) and so may not be representative of 
other countries.  
The only prior comparison of international mortality rates was by Hubbard et al in 
1996, where data from seven countries (mainly from the 1980s) were used to compare 
cause of death from cryptogenic fibrosing alveolitis (CFA) and post-inflammatory fibrosis 
(PIF) (3). The authors found an increase in mortality from CFA over time for England & 
Wales, Scotland, Canada and Australia, but no increase for Germany or New Zealand, and a 
fall for the USA. There was considerable variation in mortality rates across countries. 
Mannino et al looked at US multiple cause mortality data for a similar period, and noted a 
slight increase in mortality from IPF over time, although with much lower rates than in the 
UK (11). The authors speculated that part of this might be due to coding practice in the USA, 
noting that PIF (ICD-9 code 515) featured more prominently than IPF (ICD -9 code 516.3) 
under the subheadings for ‘fibrosis’, in contrast to the UK where CFA featured more 
prominently under the subheading for ‘alveolitis’. Olson et al updated this work by looking 
at US mortality rates from 1992-2003 (4), and noted a continued rise in mortality rates. 
Reasons postulated for the increase in mortality over this time period included changing 
smoking patterns in previous decades, greater use of high-resolution computed 
tomography, and a stricter classification system that saw IPF more explicitly linked with the 
usual interstitial pneumonia pattern of disease, which has a poorer prognosis (18). Our data 
suggest that while deaths from IPF-CS continue to increase in the USA, age-standardised 
rates have gone up less since 2003, and for J84.1 coding specifically appear to have 
plateaued. This is in contrast to England & Wales where rates are much higher and 
increasing.  
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The trend for increasing mortality from IPF-CS worldwide could reflect a true 
increase in disease incidence, but alternative explanations require consideration. These 
include greater physician awareness of the diagnosis, increasing use of diagnostic imaging, a 
desire amongst specialists to ‘categorise’ previously-labelled non-specific disease, reduced 
coding of pneumonia as an underlying cause of death due to ICD-10 guidance favouring 
chronic conditions such as respiratory and neurological disorders, and improved 
management of other chronic conditions such as cardiovascular disease, reducing deaths 
from competing causes. It is unclear how much the variation between countries reflects true 
differences in disease or the above factors. For example, the contrast between the 
proportion of deaths due to ‘unspecified’ interstitial lung disease in Japan (70-75%) and 
elsewhere (10-20%) warrants further exploration. Previous literature has suggested a lower 
incidence of IPF in East Asia (19, 20) although this likely relates to sampling of insurance 
databases featuring mainly severe disease. Assessment of data from other countries in East 
Asia would be very useful to explore these patterns further. 
There are three reasons why mortality from IPF-CS in the USA may not be increasing 
as much as elsewhere in the world. It may be that the true incidence of IPF is less in the 
USA, that it is underdiagnosed, or that it is being coded incorrectly. The suggestion of poor 
coding noted by Mannino et al (11) is supported by Coultas and Hughes’ death certificate 
study (5) that showed interstitial lung disease listed as an underlying cause of death in only 
23% of known patients (and anywhere on the death certificate in 46%) – less than Johnston 
et al’s similar work in the UK (15) where the rates were 38% and 56% respectively. It seems 
likely that coding of IPF has improved in the USA over time but it may still be suboptimal. 
Fell et al showed that the combination of increasing age and suggestive radiology could 
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reasonably predict IPF in unclear cases without the need for surgical lung biopsy (16), but it 
may be that there is reluctance to code the diagnosis without biopsy evidence. On the other 
hand, Fernandez-Perez et al (21) investigated the incidence of IPF in Minnesota from 1997 
to 2005 with thorough case ascertainment and review, and also noted a decline in 
incidence. A further validation study of death certification in the USA would be useful to 
explore the reliability of coding further.   
If mortality rates from IPF-CS continue to increase as expected, the current year 
could potentially see anywhere from 28000-65000 deaths from IPF across Europe (using our 
lowest and highest mortality rates for underlying cause of death data (table 3), summary 
estimates for yearly increase, and a European population of approximately 740 million), 
which could equate to 42000-95000 clinical cases, loosely assuming the 2/3 percentage of 
cases dying from IPF found in our cohort to be representative of the wider population. For 
the USA the numbers would be approximately 13000-17000 deaths and 19000-25000 cases. 
Using the strictest code (J84.1), assuming rates continued to increase, there would be a 
doubling of deaths from IPF-CS in 36 years. 
In summary, we have assessed mortality from IPF-CS across several countries, and 
demonstrated that it continues to increase with time in most countries studied, with some 
geographical variations. However, rates are reasonably consistent, with less variation than 
was evident in previous work (3), suggesting we may be approaching the true level. With 
new drugs for IPF on the market, it is important that there are reliable estimates of global 
disease burden. Increasing mortality rates may be due to true increases in incidence, but it 
is likely that some of the trends relate to changes in diagnostic or coding practices. 
Increasing openness, detail and accuracy with death certification is likely to improve the 
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utility of registration systems in future, and prospective IPF registries being set up in various 
countries may provide a linked resource to help validate routine mortality data. Recent 
international guidance from the American Thoracic Society, European Respiratory Society, 
Japanese Respiratory Society, and Latin American Thoracic Association published in 2011 
(14) should help standardise and encourage specific diagnosis and a follow-up to the current 
study in several years would be useful to assess the impact. 
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Figure legends  
Figure 1: A - Age-standardised mortality rates from J84 (‘other interstitial pulmonary diseases’) for 
selected countries by year, using underlying cause of death data.  Age-standardised to 2013 
European Standard Population. B - Meta-analysis of mortality rate ratios for annual increase in 
mortality from J84 over time, for underlying cause of death data, using random effects model. 
Figure 2: A - Age-standardised mortality rates from J84.1 (‘other interstitial pulmonary diseases with 
fibrosis’) for selected countries by year, using underlying cause of death data. Age-standardised to 
2013 European Standard Population. B - Meta-analysis of mortality rate ratios for annual increase in 
mortality from J84.1 over time, for underlying cause of death data, using random effects model. 
Figure 3: Age-standardised mortality rates from J84.1 (‘other interstitial pulmonary diseases with 
fibrosis’) for England & Wales, Australia and USA over time, using multiple cause of death data. Age-
standardised to 2013 European Standard Population. 
 
 
 
 
 
 
 
 
 
20 
 
Tables 
 
Table 1:  Countries included in analysis, with years of data and number of deaths per available 
ICD-10 code (J84: other interstitial pulmonary diseases; J84.1: other interstitial 
pulmonary diseases with fibrosis; J84.9: interstitial pulmonary disease, unspecified) 
Country Years of data analysed Deaths from J84 Deaths from J84.1 
Deaths from J84.1 and 
J84.9 (combined) 
Underlying cause of death data 
England & Wales 2001-2012 38861 34473 38426 
Australia 2000-2011 9325 7754 9182 
Canada 2000-2011 17792 15350 17588 
Japan 2009-2011 40928 n/a n/a 
Northern Ireland 2009-2011 398 n/a n/a 
New Zealand 2006-2010 699 n/a n/a 
Scotland 2001-2012 4341 n/a n/a 
Spain 
2000-2004, 2006-2011 
18563 16840 18344 
Sweden 2000-2012 4153 n/a n/a 
USA 1999-2010 168637 135460 166222 
Multiple cause of death data 
England & Wales 
2001-2012 65770 59734 65643 
Australia  
2000-2011 17588 14829 17501 
USA 
1999-2010 
220075 
(excluding 2006/07 - 
outlier data) 
214794 262595 
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Table 2:  Crude and age-standardised mortality rates per 100,000 population from J84 (‘other 
interstitial pulmonary diseases’), using underlying cause of death data 
Country Crude mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  4.55 4.75 4.93 5.26 5.26 5.47 5.92 6.28 6.25 6.81 7.64 8.22 
Australia 3.09 3.42 3.66 3.37 3.49 3.08 3.77 3.78 4.26 4.12 4.68 4.44  
Canada 3.55 3.80 3.75 3.66 4.58 4.96 4.66 4.85 4.89 5.14 5.30 5.42  
Japan          9.69 10.38 11.08  
Northern Ireland          5.91 6.76 9.37  
New Zealand       2.75 3.36 3.40 3.31 3.52   
Scotland  4.66 5.64 5.83 5.81 6.63 6.76 7.27 7.72 7.72 7.79 9.30 8.88 
Spain 2.96 3.22 3.48 3.61 3.62  3.77 4.30 4.05 4.15 4.56 4.74  
Sweden 2.54 2.69 3.09 3.25 3.54 3.55 3.51 3.42 3.66 3.69 4.11 3.88 4.25 
USA 4.40 4.59 4.18 4.38 5.11 4.86 4.97 5.01 5.15 5.19 5.27   
              
Country Age-standardised mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  6.39 6.19 6.42 6.82 6.72 6.97 7.57 7.93 7.85 8.47 9.41 9.84 
Australia 5.11 5.63 5.89 5.33 5.41 4.78 5.72 5.69 6.46 6.11 6.87 6.49  
Canada 5.93 6.30 6.05 5.81 7.31 7.74 7.11 7.21 7.14 7.36 7.57 7.52  
Japan          9.42 9.93 10.26  
Northern Ireland          8.22 9.80 13.36  
New Zealand       4.79 5.74 5.52 5.35 5.55   
Scotland  6.43 7.47 7.84 7.67 8.82 8.82 9.26 9.55 9.72 9.70 11.34 10.71 
Spain 3.73 4.07 4.37 4.47 4.51  4.63 5.23 4.87 4.91 5.33 5.38  
Sweden 2.84 3.10 3.59 3.72 4.01 4.07 4.04 3.90 4.13 4.14 4.60 4.37 4.68 
USA 7.01 7.22 6.57 6.86 7.95 7.50 7.63 7.62 7.76 7.71 7.80   
Age-standardised to 2013 European Standard Population 
 
 
 
Table 3: Crude and age-standardised mortality rates per 100,000 population from J84.1 (‘other 
interstitial pulmonary diseases with fibrosis’) over time, using underlying cause of death 
data 
Country Crude mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  4.33 4.48 4.61 4.87 4.81 4.88 5.28 5.50 5.32 5.77 6.59 6.90 
Australia 2.56 2.89 3.14 2.90 2.97 2.64 3.13 3.23 3.57 3.31 3.80 3.47  
Canada 3.06 3.21 3.30 3.18 4.05 4.34 4.11 4.18 4.21 4.42 4.43 4.60  
Spain 2.78 3.01 3.28 3.37 3.39  3.43 3.92 3.65 3.71 3.94 4.09  
USA 3.48 3.63 3.40 3.61 4.23 3.99 4.00 4.04 4.11 4.09 4.12   
Country Age-standardised mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  6.09 5.84 6.03 6.33 6.15 6.23 6.75 6.96 6.71 7.19 8.13 8.28 
Australia 4.23 4.80 5.04 4.60 4.65 4.13 4.74 4.84 5.44 4.97 5.59 5.08  
Canada 5.09 5.40 5.36 5.09 6.47 6.82 6.29 6.25 6.16 6.33 6.33 6.38  
Spain 3.51 3.80 4.11 4.17 4.21  4.22 4.78 4.40 4.40 4.63 4.64  
USA 5.62 5.78 5.40 5.70 6.62 6.21 6.18 6.21 6.24 6.14 6.16   
Age-standardised to 2013 European Standard Population 
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Table 4: Deaths, crude and age-standardised mortality rates, Poisson regression modelling and 
rate ratios for annual increase in mortality for J84.1 (‘other interstitial pulmonary 
diseases with fibrosis’) for England & Wales (E&W), Australia and USA, using multiple 
cause of death data, from 2001-2010 
 
Deaths 
Person 
years 
(millions) 
Crude 
mortality 
rate (per 
100,000 
population) 
Age-
standardised 
mortality 
rate (per 
100,000 
population) 
Mutually adjusted (for age 
and sex) mortality rate ratio 
(95% confidence intervals) 
Overall data       
Sex       
 Female 109664 1887.95 5.81 6.73 1.00  
 Male 133081 1825.06 7.29 13.53 1.78 (1.77-1.79)* 
Age group (years)       
 0-44 3304 2308.71 0.14 0.11 0.01 (0.01-0.01) 
 45-54 7311 524.15 1.39 1.13 0.07 (0.06-0.07)) 
 55-64 20991 394.75 5.32 5.10 0.25 (0.25-0.25) 
 65-74 53786 254.38 21.14 22.00 1.00  
 75-84 95554 168.54 56.69 63.08 2.76 (2.73-2.79) 
 85+ 61799 62.47 98.92 114.40 5.13 (5.08-5.19)† 
Country       
 E&W 47285 537.91 8.79 11.37 1.00  
 Australia 12440 204.85 6.07 9.47 0.83 (0.81-0.85)* 
 USA 183020 2970.25 6.16 9.55 0.87 (0.86-0.88)* 
       
By male sex       
 Age group (years)      
 0-44 1545 1168.63 0.13 0.11 0.00 (0.00-0.01) 
 45-54 3913 258.06 1.52 1.29 0.05 (0.05-0.06) 
 55-64 12539 191.35 6.55 6.52 0.24 (0.23-0.24) 
 65-74 33146 118.12 28.06 29.59 1.00  
 75-84 54582 69.57 78.45 85.00 2.80 (2.76-2.84) 
 85+ 27356 19.33 141.56 153.53 5.06 (4.98-5.14)† 
 Country      
 E&W 29651 263.89 11.24 15.98 1.00  
 Australia 7384 101.79 7.25 12.70 0.76 (0.74-0.78)* 
 USA 96046 1459.37 6.58 11.90 0.74 (0.73-0.75)* 
 
By female sex       
 Age group (years)      
 0-44 1759 1140.09 0.15 0.12 0.01 0.01-0.01 
 45-54 3398 266.09 1.28 0.98 0.84 0.08-0.09 
 55-64 8452 203.40 4.16 3.68 0.27 0.27-0.28 
 65-74 20640 136.26 15.15 14.42 1.00  
 75-84 40972 98.97 41.40 41.16 2.73 2.69-2.78 
 85+ 34443 43.15 79.83 75.27 5.27 5.18-5.36† 
 Country      
 E&W 17634 274.02 6.44 6.75 1.00  
 Australia 5056 103.06 4.91 6.25 0.94 (0.91-0.97)* 
 USA 86974 1510.88 5.76 7.20 1.09 (1.07-1.10)* 
 
Country Rate ratio 95% Confidence Intervals p value 
England & Wales 1.03 1.027-1.032 <0.001 
Australia 1.01 1.00-1.01 0.016 
USA 1.00 0.999-1.001 0.701 
Age-standardised to 2013 European Standard Population. *p<0.001, †p for trend<0.001 
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Table 5: Deaths, crude and age-standardised mortality rates, Poisson regression modelling and 
rate ratios for annual increase in mortality for J84.1 (‘other interstitial pulmonary 
diseases with fibrosis’) for five most populous states in USA, using multiple cause of 
death data, from 2001-2010 
 
Deaths 
Person 
years 
(millions) 
Crude 
mortality 
rate (per 
100,000 
population) 
Age-
standardised 
mortality 
rate (per 
100,000 
population) 
Mutually adjusted (for age 
and sex) mortality rate ratio 
(95% confidence intervals) 
Overall data       
Sex       
 Female 30845 603.45 5.11 6.71 1.00  
 Male 34024 585.56 5.81 10.82 1.61 (1.58-1.63)* 
Age group (years)       
 0-44 327 762.01 0.04 0.03 0.01 (0.01-0.01) 
 45-54 2332 164.39 1.42 1.43 0.07 (0.07-0.08) 
 55-64 6013 117.28 5.13 5.25 0.27 (0.26-0.28) 
 65-74 14277 75.89 18.81 19.37 1.00  
 75-84 25018 50.79 49.26 52.05 2.69 (2.63-2.75) 
 85+ 16902 18.66 90.59 98.87 5.21 (5.09-5.32) † 
State       
 California 19928 392.97 5.07 9.00 1.00  
 Florida 14156 193.81 7.30 8.53 0.96 (0.94-0.98)* 
 Illinois 8005 138.90 5.76 9.18 1.03 (1.01-1.06) ‡ 
 New York 9043 210.81 4.29 6.42 0.71 (0.70-0.73)* 
 Texas 13737 252.51 5.44 10.69 1.21 (1.18-1.23)* 
       
By male sex       
 Age group (years)      
 0-44 133 387.06 0.03 0.03 0.01 (0.00-0.01) 
 45-54 1211 80.73 1.50 1.53 0.06 (0.06-0.67) 
 55-64 3446 56.07 6.15 6.26 0.26 (0.25-0.27) 
 65-74 8333 34.73 24.00 24.20 1.00  
 75-84 13647 20.95 65.14 65.56 2.73 (2.65-2.80) 
 85+ 7254 6.02 120.44 120.30 5.07 (4.91-5.23) † 
 State      
 California 10460 195.57 5.35 11.05 1.00  
 Florida 7799 94.72 8.23 10.65 0.98 (0.95-1.01) § 
 Illinois 4096 68.10 6.01 11.43 1.05 (1.01-1.09) || 
 New York 4726 101.84 4.64 8.17 0.75 (0.72-0.77) * 
 Texas 6943 125.32 5.54 12.79 1.17 (1.14-1.21) * 
 
By female sex       
 Age group (years)      
 0-44 194 374.96 0.05 0.04 0.01 (0.007-0.009) 
 45-54 1121 83.65 1.34 1.33 0.94 (0.09-0.10) 
 55-64 2567 61.21 4.19 4.24 0.29 (0.28-0.30) 
 65-74 5944 41.16 14.44 14.56 1.00  
 75-84 11371 29.83 38.11 38.55 2.65 (2.57-2.74) 
 85+ 9648 12.63 76.36 77.43 5.36 (5.19-5.53) † 
 State      
 California 9468 197.40 4.80 6.94 1.00  
 Florida 6357 99.09 6.42 6.40 0.93 (0.90-0.96) )* 
 Illinois 3909 70.80 5.52 6.93 1.01 (0.98-1.05) ¶ 
 New York 4317 108.97 3.96 4.67 0.68 (0.66-0.71) )* 
 Texas 6794 127.19 5.34 8.59 1.24 (1.20-1.28) )* 
 
State Rate ratio 95% Confidence Intervals p value 
California 0.99 0.98-0.99 <0.001 
Florida 1.01 1.00-1.01 0.016 
Illinois 1.01 1.00-1.01 0.056 
New York 1.00 1.00-1.01 0.161 
Texas 0.99 0.98-0.99 <0.001 
Age-standardised to 2013 European Standard Population.*p<0.001, †p for trend<0.001, ‡ p=0.015, § p=0.158,  
|| p=0.006, ¶ p=0.517 
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Figure 3 
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Figure E1: Meta-analysis of mortality rate ratios for male vs female sex, for J84 (‘other interstitial 
pulmonary diseases’) over time, using random effects model 
 
 
Mortality using underlying cause of death data – J84.1 and J84.9 combined coding 
Using J84.1+J84.9 combined coding (‘other interstitial pulmonary diseases with 
fibrosis’ and ‘interstitial pulmonary disease, unspecified’), crude and age-standardised 
mortality rates were higher than more specific J84.1 coding (Table E1 / Figure E2). Age-
standardised mortality rates increased to 9.76 per 100,000 (England & Wales, 2012), 7.72 
per 100,000 (USA, 2010), 7.45 per 100,000 (Canada, 2011), 6.38 per 100,000 (Australia, 
2011), and 5.25 per 100,000 (Spain, 2011). Rate ratios over time were essentially equivalent 
to J84 figures. Meta-analysis again showed an overall 3% increase over time (rate ratio 1.03, 
95% CI 1.01-1.04, p<0.001) (Figure E3). 
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Table E1: Crude and age-standardised mortality (standardised to 2013 European Standard 
Population) per 100,000 population from J84.1+J84.9 (‘other interstitial pulmonary 
diseases with fibrosis’ and ‘interstitial pulmonary disease, unspecified’) over time 
Country Crude mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  4.50 4.71 4.87 5.21 5.20 5.40 5.85 6.19 6.15 6.72 7.57 8.15 
Australia 3.07 3.39 3.61 3.33 3.41 3.05 3.71 3.77 4.18 3.99 4.63 4.36  
Canada 3.51 3.75 3.70 3.60 4.55 4.92 4.60 4.79 4.82 5.08 5.22 5.37  
Spain 2.93 3.19 3.43 3.58 3.57  3.74 4.28 4.01 4.11 4.47 4.63  
USA 4.33 4.52 4.10 4.31 5.04 4.81 4.86 4.95 5.09 5.13 5.20   
Country Age-standardised mortality rates per 100,000 population over time 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
England & Wales  6.33 6.15 6.35 6.76 6.66 6.89 7.47 7.83 7.74 8.37 9.33 9.76 
Australia 5.08 5.57 5.78 5.28 5.31 4.74 5.64 5.65 6.35 5.93 6.79 6.38  
Canada 5.88 6.23 6.00 5.74 7.26 7.69 7.03 7.13 7.06 7.29 7.48 7.45  
Spain 3.69 4.04 4.31 4.43 4.45  4.60 5.20 4.82 4.86 5,24 5.25  
USA 6.93 7.13 6.46 6.77 7.86 7.43 7.47 7.55 7.69 7.63 7.72   
              
Age-standardised to 2013 European Standard Population 
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Figure E2: Age-standardised mortality rates from J84.1+J84.9 (‘other interstitial pulmonary diseases 
with fibrosis’ and ‘interstitial pulmonary disease, unspecified’) for selected countries by 
year, using underlying cause of death data. Age-standardised to 2013 European Standard 
Population. 
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Figure E3: Meta-analysis of mortality rate ratios for annual increase in mortality from J84.1+J84.9 
(‘other interstitial pulmonary diseases with fibrosis’ and ‘interstitial pulmonary disease, 
unspecified’) over time, using random effects model. 
 
 
Mortality using multiple cause of death data – J84.1 and J84.9 combined coding 
Using multiple cause of death data from the USA, Australia and England & Wales, 
age-standardised mortality rates from J84.1+J84.9 were highest in England & Wales – 14.65 
per 100,000 in 2010, compared to 11.99 per 100,000 in Australia, and 11.73 per 100,000 in 
the USA (Figure E4).  
 
As with J84.1 coding, mortality rate ratios over time were similar to underlying cause 
of death data for England & Wales, but the rate of increase was less for Australia, with no 
increase over time in the USA. Using Poisson regression for combined USA, Australia and 
England & Wales data (years where data was available for all three countries) there was a 
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marginally reduced chance of having a diagnostic code of either J84.1 or J84.9 in the USA 
(rate ratio 0.98, 95% CI 0.97-0.99, p<0.001) and a slightly greater reduced chance in 
Australia (rate ratio 0.90, 95% CI 0.88-0.91, p<0.001) (Table E2a). The mutually adjusted (for 
age and sex) mortality rate ratio for annual change for J84.1+J84.9 was 1.01 (95% CI 1.007-
1.009, p for trend<0.001). Meta-analysis using the random effects method (including all 
years with data available) showed individual rates of 1.04 for England & Wales (95% CI 
1.038-1.043, p<0.001), 1.01 for Australia (95% CI 1.01-1.02, p<0.001), and 1.00 for USA (95% 
CI 1.00-1.01, p<0.001), with an overall rate of 1.02 (95% CI 0.99-1.04, p<0.001) (Table E2b).  
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Figure E4: Age-standardised mortality rates from J84.1+J84.9 (‘other interstitial pulmonary diseases 
with fibrosis’ and ‘interstitial pulmonary disease, unspecified’) for England & Wales, 
Australia and USA, using multiple cause of death data, over time. Age-standardised to 
2013 European Standard Population. 
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Table E2a: Deaths, crude and age-standardised mortality rates, and Poisson regression modelling 
for J84.1+J84.9 (‘other interstitial pulmonary diseases with fibrosis’ and ‘interstitial 
pulmonary disease, unspecified’) for England & Wales (E&W), Australia and USA, using 
multiple cause of death data, from 2001-2010 
 
Deaths 
Person 
years 
(millions) 
Crude 
mortality 
rate (per 
100,000 
population) 
Age-
standardised 
mortality 
rate (per 
100,000 
population) 
Mutually adjusted mortality 
rate ratio (95% confidence 
intervals) 
Sex       
 Female 132728 1887.95 7.03 7.83 1.00  
 Male 157565 1825.06 8.63 15.48 1.73 (1.72-1.74)* 
Age group (years)       
 0-44 5623 2308.71 0.24 0.18 0.01 (0.01-0.01) 
 45-54 9803 524.15 1.87 1.47 0.07 (0.07-0.07) 
 55-64 26356 394.75 6.68 6.12 0.26 (0.26-0.27) 
 65-74 64119 254.38 25.21 25.41 1.00  
 75-84 112026 168.54 66.47 71.81 2.71 (2.69-2.74) 
 85+ 72366 62.47 115.84 129.95 5.01 (4.96-5.07)† 
Country       
 E&W 51234 537.91 9.52 12.28 1.00  
 Australia 14611 204.85 7.13 11.07 0.90 (0.88-0.91)* 
 USA 224448 2970.25 7.56 11.61 0.98 (0.97-0.99)* 
       
Age-standardised to 2013 European Standard Population. *p<0.001, †p for trend<0.001 
 
Table E2b: Rate ratios for annual increase in mortality from J84.1+J84.9 (‘other interstitial 
pulmonary diseases with fibrosis’ and ‘interstitial pulmonary disease, unspecified’) for 
England & Wales, Australia and USA, using multiple cause of death data, from 2001-10 
Country 
 
Rate ratio 
95% Confidence 
Intervals 
p value 
England & Wales 
Australia 
USA 
1.04 1.038-1043 <0.001 
1.01 1.01-1.02 <0.001 
1.00 1.00-1.01 <0.001 
 
 
Subnational data from the USA using J84.1+J84.9 multiple cause of death data 
showed crude mortality rates ranging from 3.85 per 100,000 (Nevada) to 13.26 per 100,000 
(Vermont). Looking at the top 5 most populous states (California, Texas, New York, Florida, 
Illinois) with full age-specific data and only few missing values, the highest rates were in 
Texas (crude rate 6.25 per 100,000, age-standardised rate 12.20 per 100,000) and lowest in 
New York (crude rate 5.32 per 100,000, age standardised rate 7.93 per 100,000) (Table E3a). 
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While crude mortality rates increased over time, age-standardised rates remained relatively 
stable. Rate ratios for annual increase over time showed a 1% increase for Florida, Illinois 
and New York, a marginal increase for California and a marginal decrease for Texas (Table 
E3b), with an overall rate ratio by meta-analysis of 1.00 (95% CI 1.00-1.01). 
Table E3a: Deaths, crude and age-standardised mortality rates, and Poisson regression modelling 
for J84.1+J84.9 (‘other interstitial pulmonary diseases with fibrosis’ and ‘interstitial 
pulmonary disease, unspecified’) for five most populous states in USA, using multiple 
cause of death data, from 2001-2010 
 
Deaths 
Person 
years 
(millions) 
Crude 
mortality 
rate (per 
100,000 
population) 
Age-
standardised 
mortality 
rate (per 
100,000 
population) 
Mutually adjusted mortality 
rate ratio (95% confidence 
intervals) 
Sex       
 Female 37577 603.45 6.23 8.04 1.00  
 Male 40567 585.56 6.93 12.69 1.57 (1.55-1.59)* 
Age group (years)       
 0-44 360 762.01 0.05 0.04 0.01 (0.00-0.01) 
 45-54 2773 164.39 1.69 1.64 0.07 (0.07-0.08) 
 55-64 7557 117.28 6.44 6.43 0.28 (0.27-0.28) 
 65-74 17358 75.89 22.87 23.22 1.00  
 75-84 29954 50.79 58.98 61.55 2.65 (2.60-2.70) 
 85+ 20142 18.66 107.96 115.06 5.07 (4.97-5.17)† 
State       
 California 25969 392.97 6.61 11.66 1.00  
 Florida 16134 193.81 8.32 9.70 0.84 (0.82-0.85)* 
 Illinois 9046 138.90 6.51 10.35 0.90 (0.87-0.92)* 
 New York 11218 210.81 5.32 7.93 0.68 (0.66-0.69)* 
 Texas 15777 252.51 6.25 12.20 1.06 (1.04-1.08)* 
       
Age-standardised to 2013 European Standard Population. *p<0.001, †p for trend<0.001 
Table E3b: Rate ratios for annual increase in mortality from J84.1+J84.9 (‘other interstitial 
pulmonary diseases with fibrosis’ and ‘interstitial pulmonary disease, unspecified’) for 
five most populous states in USA, using multiple cause of death data, from 2001-2010 
Country 
 
Rate ratio 
95% Confidence 
Intervals 
p value 
California 
Florida 
Illinois 
New York 
Texas 
1.00 1.00-1.01 0.433 
1.01 1.00-1.01 0.001 
1.01 1.01-1.02 <0.001 
1.01 1.00-1.02 <0.001 
0.99 0.99-1.00 <0.001 
 
 
 
 
